Inhibition of SLC13A3 in syngeneic mouse tumor models synergizes with CTLA-4 blockade therapy to promote tumor-infiltrating T-cell immune responses, providing a potential novel therapeutic strategy for multiple cancer types [91]. This evidence concerns the gene CTLA4 and neoplasm.